Public annual accounts

AERTS PHARMA financials

Name: AERTS PHARMA financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for AERTS PHARMA, with comparable measures and links to available source documents.

Company overview

Registry number

0886207737

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 29, 2026

Financial evidence

Latest movements for AERTS PHARMA

2025 versus 2024

Operating line: €368,107
EBITDA: €263,727
Total assets: €1,042,560
Equity: €53,884

EBITDA margin +71.6% · Equity ratio +5.2%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202531 Dec 2025	€368,107	€263,727	€1,042,560	€53,884	-
202431 Dec 2024	€411,395	€304,676	€956,830	€53,868	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report